Hyrimoz Purple Book BLA 761071
- BLA number
- 761071
- Proprietary names
- Hyrimoz
- Proper names
- adalimumab-adaz
- Applicant
- Sandoz Inc.
- Center
- CDER
- First observed release
- 2020-02-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | Hyrimoz | adalimumab-adaz | 351(k) Interchangeable | 40MG/0.8ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2018-10-30 | |
| 002 | Hyrimoz | adalimumab-adaz | 351(k) Interchangeable | 40MG/0.8ML | Injection | Subcutaneous | Autoinjector | Rx | Licensed | 2018-10-30 | |
| 003 | Hyrimoz | adalimumab-adaz | 351(k) Interchangeable | 10MG/0.2ML | Injection | Subcutaneous | Pre-Filled Syringe | Disc | Licensed | 2022-03-28 | |
| 004 | Hyrimoz | adalimumab-adaz | 351(k) Interchangeable | 40MG/0.4ML | Injection | Subcutaneous | Autoinjector | Rx | Licensed | 2023-03-20 | |
| 005 | Hyrimoz | adalimumab-adaz | 351(k) Interchangeable | 80MG/0.8ML | Injection | Subcutaneous | Autoinjector | Rx | Licensed | 2023-03-20 | |
| 006 | Hyrimoz | adalimumab-adaz | 351(k) Interchangeable | 20MG/0.4ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2023-03-20 | |
| 007 | Hyrimoz | adalimumab-adaz | 351(k) Interchangeable | 40MG/0.4ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2023-03-20 | |
| 008 | Hyrimoz | adalimumab-adaz | 351(k) Interchangeable | 80MG/0.8ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2023-03-20 | |
| 009 | Hyrimoz | adalimumab-adaz | 351(k) Interchangeable | 10MG/0.1ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2023-03-20 | |
| 010 | Hyrimoz | adalimumab-adaz | 351(k) Interchangeable | 20MG/0.2ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2023-03-20 | |
Reference Biological Product#
BLA, Proprietary name, Proper name table| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|
| 125057 | Humira | adalimumab | 351(a) | Rx | 2026-06-01 |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2025-08-01 | U | 002 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2025-08-01 | U | 004 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2025-08-01 | U | 005 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2025-05-01 | U | 007 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2025-02-01 | U | 008 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2025-02-01 | U | 009 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2025-02-01 | U | 010 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2025-01-01 | U | 008 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2025-01-01 | U | 009 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2025-01-01 | U | 010 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2024-09-01 | U | 003 | Hyrimoz | 351(k) Interchangeable | Disc | Sandoz Inc. |
| 2024-04-01 | U | 001 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2024-04-01 | U | 003 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2024-04-01 | U | 005 | Hyrimoz | 351(k) Biosimilar | Rx | Sandoz Inc. |
| 2024-04-01 | U | 006 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2024-04-01 | U | 008 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2024-04-01 | U | 009 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2024-04-01 | U | 010 | Hyrimoz | 351(k) Interchangeable | Rx | Sandoz Inc. |
| 2023-03-01 | N | 004 | Hyrimoz | 351(k) Biosimilar | Rx | Sandoz Inc. |
| 2023-03-01 | N | 005 | Hyrimoz | 351(k) Biosimilar | Rx | Sandoz Inc. |
| 2023-03-01 | N | 006 | Hyrimoz | 351(k) Biosimilar | Rx | Sandoz Inc. |
| 2023-03-01 | N | 007 | Hyrimoz | 351(k) Biosimilar | Rx | Sandoz Inc. |
| 2023-03-01 | N | 008 | Hyrimoz | 351(k) Biosimilar | Rx | Sandoz Inc. |
| 2023-03-01 | N | 009 | Hyrimoz | 351(k) Biosimilar | Rx | Sandoz Inc. |
| 2023-03-01 | N | 010 | Hyrimoz | 351(k) Biosimilar | Rx | Sandoz Inc. |
| 2022-03-01 | N | 003 | Hyrimoz | 351(k) Biosimilar | Rx | Sandoz Inc. |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2025-08-01 | 002 | Hyrimoz | 351(k) Interchangeable | Rx | Licensed | 2018-10-30 |
| 2025-08-01 | 004 | Hyrimoz | 351(k) Interchangeable | Rx | Licensed | 2023-03-20 |
| 2025-08-01 | 005 | Hyrimoz | 351(k) Interchangeable | Rx | Licensed | 2023-03-20 |
| 2025-05-01 | 007 | Hyrimoz | 351(k) Interchangeable | Rx | Licensed | 2023-03-20 |
| 2024-09-01 | 003 | Hyrimoz | 351(k) Interchangeable | Disc | Licensed | 2022-03-28 |
| 2024-04-01 | 001 | Hyrimoz | 351(k) Interchangeable | Rx | Licensed | 2018-10-30 |
| 2024-04-01 | 003 | Hyrimoz | 351(k) Interchangeable | Rx | Licensed | 2022-03-28 |
| 2024-04-01 | 006 | Hyrimoz | 351(k) Interchangeable | Rx | Licensed | 2023-03-20 |
| 2024-04-01 | 008 | Hyrimoz | 351(k) Interchangeable | Rx | Licensed | 2023-03-20 |
| 2024-04-01 | 009 | Hyrimoz | 351(k) Interchangeable | Rx | Licensed | 2023-03-20 |
| 2024-04-01 | 010 | Hyrimoz | 351(k) Interchangeable | Rx | Licensed | 2023-03-20 |
| 2023-03-01 | 004 | Hyrimoz | 351(k) Biosimilar | Rx | Licensed | 2023-03-20 |
| 2023-03-01 | 005 | Hyrimoz | 351(k) Biosimilar | Rx | Licensed | 2023-03-20 |
| 2023-03-01 | 006 | Hyrimoz | 351(k) Biosimilar | Rx | Licensed | 2023-03-20 |
| 2023-03-01 | 007 | Hyrimoz | 351(k) Biosimilar | Rx | Licensed | 2023-03-20 |
| 2023-03-01 | 008 | Hyrimoz | 351(k) Biosimilar | Rx | Licensed | 2023-03-20 |
| 2023-03-01 | 009 | Hyrimoz | 351(k) Biosimilar | Rx | Licensed | 2023-03-20 |
| 2023-03-01 | 010 | Hyrimoz | 351(k) Biosimilar | Rx | Licensed | 2023-03-20 |
| 2022-03-01 | 003 | Hyrimoz | 351(k) Biosimilar | Rx | Licensed | 2022-03-28 |
| 2020-05-01 | 001 | Hyrimoz | 351(k) Biosimilar | Rx | Licensed | 2018-10-30 |
| 2020-05-01 | 002 | Hyrimoz | 351(k) Biosimilar | Rx | Licensed | 2018-10-30 |
| 2020-02-01 | 001 | Hyrimoz | 351(k) Biosimilar | Marketed | Licensed | 2018-10-30 |
| 2020-02-01 | 002 | Hyrimoz | 351(k) Biosimilar | Marketed | Licensed | 2018-10-30 |